Sfrp4 Expression in Thyroxine Treated Calvarial Cells

Overview

Journal Life Sci

Publisher Elsevier

Specialties Biochemistry
Biology
Physiology

Date 2022 Nov 12

PMID 36370870

Authors

Emily L Durham

Zachary J Grey

Laurel Black

R Nicole Howie

Jeremy L Barth

Beth S Lee

James J Cray

Affiliations

Soon will be listed here.

Abstract

Aims: Evidence suggests alterations of thyroid hormone levels can disrupt normal bone development. Most data suggest the major targets of thyroid hormones to be the Htra1/Igf1 pathway. Recent discovery by our group suggests involvement of targets WNT pathway, specifically overexpression of antagonist Sfrp4 in the presence of exogenous thyroid hormone.

Main Methods: Here we aimed to model these interactions in vitro using primary and isotype cell lines to determine if thyroid hormone drives increased Sfrp4 expression in cells relevant to craniofacial development. Transcriptional profiling, bioinformatics interrogation, protein and function analyses were used.

Key Findings: Affymetrix transcriptional profiling found Sfrp4 overexpression in primary cranial suture derived cells stimulated with thyroxine in vitro. Interrogation of the SFRP4 promoter identified multiple putative binding sites for thyroid hormone receptors. Experimentation with several cell lines demonstrated that thyroxine treatment induced Sfrp4 expression, demonstrating that Sfrp4 mRNA and protein levels are not tightly coupled. Transcriptional and protein analyses demonstrate thyroid hormone receptor binding to the proximal promoter of the target gene Sfrp4 in murine calvarial pre-osteoblasts. Functional analysis after thyroxine hormone stimulation for alkaline phosphatase activity shows that pre-osteoblasts increase alkaline phosphatase activity compared to other cell types, suggesting cell type susceptibility. Finally, we added recombinant SFRP4 to pre-osteoblasts in combination with thyroxine treatment and observed a significant decrease in alkaline phosphatase positivity.

Significance: Taken together, these results suggest SFRP4 may be a key regulatory molecule that prevents thyroxine driven osteogenesis. These data corroborate clinical findings indicating a potential for SFRP4 as a diagnostic or therapeutic target for hyperostotic craniofacial disorders.

Citing Articles

Manzamine-A Alters Calvarial Osteoclast Function.

Maykovich T, Hardy S, Hamann M, Cray J J Nat Prod. 2024; 87(3):560-566.

PMID: 38383319 PMC: 11173362. DOI: 10.1021/acs.jnatprod.3c01097.

References

Maruyama T, Mirando A, Deng C, Hsu W . The balance of WNT and FGF signaling influences mesenchymal stem cell fate during skeletal development. Sci Signal. 2010; 3(123):ra40. PMC: 2902546. DOI: 10.1126/scisignal.2000727. View

Sievers F, Wilm A, Dineen D, Gibson T, Karplus K, Li W . Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011; 7:539. PMC: 3261699. DOI: 10.1038/msb.2011.75. View

Cordero D, Brugmann S, Chu Y, Bajpai R, Jame M, Helms J . Cranial neural crest cells on the move: their roles in craniofacial development. Am J Med Genet A. 2011; 155A(2):270-9. PMC: 3039913. DOI: 10.1002/ajmg.a.33702. View

Deshmukh A, Kumar S, Arfuso F, Newsholme P, Dharmarajan A . Secreted Frizzled-related protein 4 (sFRP4) chemo-sensitizes cancer stem cells derived from human breast, prostate, and ovary tumor cell lines. Sci Rep. 2017; 7(1):2256. PMC: 5442130. DOI: 10.1038/s41598-017-02256-4. View

Chawla R, Alden T, Bizhanova A, Kadakia R, Brickman W, Kopp P . Squamosal Suture Craniosynostosis Due to Hyperthyroidism Caused by an Activating Thyrotropin Receptor Mutation (T632I). Thyroid. 2015; 25(10):1167-72. DOI: 10.1089/thy.2014.0503. View

Durham E, Howie R, Black L, Bennfors G, Parsons T, Elsalanty M . Effects of thyroxine exposure on the Twist 1 +/- phenotype: A test of gene-environment interaction modeling for craniosynostosis. Birth Defects Res A Clin Mol Teratol. 2016; 106(10):803-813. PMC: 5088492. DOI: 10.1002/bdra.23543. View

Batsali A, Pontikoglou C, Koutroulakis D, Pavlaki K, Damianaki A, Mavroudi I . Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells. Stem Cell Res Ther. 2017; 8(1):102. PMC: 5406919. DOI: 10.1186/s13287-017-0555-9. View

Haraguchi R, Kitazawa R, Mori K, Tachibana R, Kiyonari H, Imai Y . sFRP4-dependent Wnt signal modulation is critical for bone remodeling during postnatal development and age-related bone loss. Sci Rep. 2016; 6:25198. PMC: 4846872. DOI: 10.1038/srep25198. View

Williams G . Thyroid hormone actions in cartilage and bone. Eur Thyroid J. 2014; 2(1):3-13. PMC: 3821494. DOI: 10.1159/000345548. View

10.

Park J, Jung J, Lee Y, Kang K . The roles of Wnt antagonists Dkk1 and sFRP4 during adipogenesis of human adipose tissue-derived mesenchymal stem cells. Cell Prolif. 2008; 41(6):859-874. PMC: 6495667. DOI: 10.1111/j.1365-2184.2008.00565.x. View

11.

Kesterke M, Judd M, Mooney M, Siegel M, Elsalanty M, Howie R . Maternal environment and craniofacial growth: geometric morphometric analysis of mandibular shape changes with in utero thyroxine overexposure in mice. J Anat. 2018; 233(1):46-54. PMC: 5987819. DOI: 10.1111/joa.12810. View

12.

Simsek Kiper P, Saito H, Gori F, Unger S, Hesse E, Yamana K . Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease. N Engl J Med. 2016; 374(26):2553-2562. PMC: 5070790. DOI: 10.1056/NEJMoa1509342. View

13.

Hashmi S, Canfield M, Marengo L, Moffitt K, Belmont J, Freedenberg D . The association between neonatal thyroxine and craniosynostosis, Texas, 2004-2007. Birth Defects Res A Clin Mol Teratol. 2012; 94(12):1004-9. DOI: 10.1002/bdra.23077. View

14.

Ehrlund A, Mejhert N, Lorente-Cebrian S, Astrom G, Dahlman I, Laurencikiene J . Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue. J Clin Endocrinol Metab. 2013; 98(3):E503-8. DOI: 10.1210/jc.2012-3416. View

15.

Wang Y, Zhang S . Expression and regulation by thyroid hormone (TH) of zebrafish IGF-I gene and amphioxus IGFl gene with implication of the origin of TH/IGF signaling pathway. Comp Biochem Physiol A Mol Integr Physiol. 2011; 160(4):474-9. DOI: 10.1016/j.cbpa.2011.08.005. View

16.

Deshmukh A, Arfuso F, Newsholme P, Dharmarajan A . Regulation of Cancer Stem Cell Metabolism by Secreted Frizzled-Related Protein 4 (sFRP4). Cancers (Basel). 2018; 10(2). PMC: 5836072. DOI: 10.3390/cancers10020040. View

17.

Sampath T, Simic P, Sendak R, Draca N, Bowe A, OBrien S . Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res. 2007; 22(6):849-59. DOI: 10.1359/jbmr.070302. View

18.

Lakatos P, Foldes J, Nagy Z, Takacs I, Speer G, Horvath C . Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism. Thyroid. 2000; 10(5):417-23. DOI: 10.1089/thy.2000.10.417. View

19.

Robin N . Molecular genetic advances in understanding craniosynostosis. Plast Reconstr Surg. 1999; 103(3):1060-70. View

20.

Ikegame M, Ishibashi O, Yoshizawa T, Shimomura J, Komori T, Ozawa H . Tensile stress induces bone morphogenetic protein 4 in preosteoblastic and fibroblastic cells, which later differentiate into osteoblasts leading to osteogenesis in the mouse calvariae in organ culture. J Bone Miner Res. 2001; 16(1):24-32. DOI: 10.1359/jbmr.2001.16.1.24. View